J&J recalls some lots of kids' Tylenol; Roche warns of children's Tamiflu shortage;

> Johnson & Johnson is recalling some lots of infants' and children's Tylenol because of a possible bacterial contamination of the popular pain and fever treatment. Report

> Roche said there's a shortage of the children's version of its Tamiflu drug, a key treatment for swine flu and seasonal flu. Report

> An appeals court on Wednesday upheld a lower court's ruling that AstraZeneca inflated the price of expensive drugs in Massachusetts. Report

> Spanish drug company Zeltia, which expects European sales of 300 million euros a year from its drug Yondelis for treating ovarian cancer, could issue shares equivalent to 2 percent of its capital, Chairman Jose Maria Fernandez Sousa-Faro said. Report

> Astellas Pharma, Japan's second-largest drugmaker, said the FDA approved a six-month extension of patent protection for its blockbuster prostate drug Flomax under its pediatric exclusivity rules. Report

> Genzyme its leukemia treatment Campath, in combination with the chemotherapy drug Fludara, met a late-stage study goal of extending life without significant progression of the disease. Report

> Analysts at J.P. Morgan initiated coverage of Biovail on Friday with an overweight rating and a price target of $19. Report

Biotech News

> Allos Therapeutics' shares were up 8 percent on the news that the FDA had approved Folotyn for use as a single agent for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Report

> Cell Therapeutics has withdrawn its European application to market lung cancer drug Opaxio. In announcing the setback earlier this week, the company cited the concerns of an EMEA committee regarding its trial design. Report

> A group of Houston investors have transformed the defunct operations of Introgen Therapeutics into a contract manufacturing organization. The Austin-based biotech was in the midst of bankruptcy proceedings after slashing its staff down to 15 and filing for Chapter 11 last December. Report

> European regulators have issued a positive recommendation for Zeltia's Yondelis, an oncology drug used in combination with Johnson & Johnson's Doxil to treat ovarian cancer. Report

And Finally... Using a new kind of clinical trial, researchers found that Teva Pharmaceuticals' Azilect may actually delay the progression of Parkinson's disease. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.